GeneDx is a biotechnology company specializing in genomic testing, particularly exome and genome sequencing, aimed at diagnosing rare and ultra-rare genetic disorders. Founded in 2000, the company is headquartered in Gaithersburg, Maryland. In 2021, GeneDx merged with Sema4 Holdings, strengthening its position in genomic testing. In 2024, the company achieved a significant financial turnaround, reporting its first adjusted net income in the third quarter and a year-over-year revenue increase of 52% to $76.6 million. GeneDx's shares are traded on NASDAQ under the symbol WGS.
Feed
There are no posts to show right now.
Folosim cookie-uri pentru a vă îmbunătăți experiența pe site-ul nostru.
